Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Catalyst Pharmaceuticals Inc (CPRX)

383 + Investors. Track Smart Money conviction in CPRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +9
Streak
3Q ▲
Buyers last Q
51%

Smart Money Signals — CPRX

Based on 388 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added CPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
388 hedge funds hold CPRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q
+29 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 51% buying

216 buying208 selling
Last quarter: 216 funds bought or added vs 208 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+42 vs last Q)

new funds entering per quarter
Funds opening a new CPRX position: 51 → 69 → 57 → 99. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 21% medium ■ 32% new
184 out of 388 hedge funds have held CPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +29% but shares only +5% — price-driven

Value
+29%
Shares
+4%
Last quarter: the total dollar value of institutional holdings rose +29%, but actual share count only changed +5%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

50 → 51 → 69 → 57 → 99 new funds/Q
New funds entering each quarter: 51 → 69 → 57 → 99. A growing number of institutions are discovering CPRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 52% veterans vs 35% newcomers

■ 52% veterans ■ 12% 1-2yr ■ 35% new
Entry-cohort mix of 392 holders: 205 (52%) are 2+ year veterans, 48 entered 1–2 years ago, and 139 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 62% AUM from top-100 funds

62% from top-100 AUM funds
54 of 387 holders are among the 100 largest funds by AUM, controlling 62% of total institutional value in CPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CPRX

In 2026 Q2, 216 hedge funds were net buyers of CPRX (99 opened a new position, 117 added to an existing one), while 208 reduced or exited (118 trimmed, 90 sold completely) — a 51% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 62% of total institutional value in CPRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +9 funds (more new holders than closures). Total institutional holders: 388.

Hedge Fund Ownership: CPRX

How many hedge funds hold CPRX — quarterly history vs. share price
Quarterly hedge fund ownership of CPRX vs. share price

Market Analysis: CPRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CPRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Loading signal freshness…
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

16 top-rated funds 2 high-conviction
Consensus
5.3
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: CPRX
383 + Investors

Track Smart Money conviction in CPRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 383 379 1.06%
13F Shares 105M 104M 0.61%
Total Value $3.11B $2.51B 24.1%
New Positions 98 57 +41
Increased Positions 112 145 -33
Closed Positions 93 49 +44
Reduced Positions 117 119 -2
Total Calls 4 4 -
Total Puts 1 4 -75.0%
PUT/CALL Ratio 0.25 1.0 Bullish

Statistics: CPRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

383 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CPRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CPRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Versor Investments LP 5.04% 76,286 $2.4M
2 Gables Capital Management INC. 4.76% 419,181 $13.2M
3 JW Asset Management, LLC 3.82% 388,392 $12.2M
4 Nexpoint Asset Management, L.P. 3.37% 1,602,557 $50.4M
5 Water Island Capital LLC 2.73% 933,819 $29.3M
6 Chicago Capital Management, LLC 2.61% 122,650 $2.9M
7 Harvest Management LLC 1.85% 150,000 $4.7M
8 Kintayl Capital LP 1.43% 114,111 $3.6M
9 Sagefield Capital LP 1.33% 569,481 $17.9M
10 Bridge City Capital, LLC 1.10% 152,684 $4.8M
11 Third Avenue Management LLC 1.06% 210,161 $6.6M
12 Clark Estates Inc/Ny 0.83% 113,918 $3.6M
13 First Trust Capital Management L.P. 0.76% 416,209 $13.1M
14 Melqart Asset Management (UK) Ltd 0.74% 247,556 $7.8M
15 GABELLI & Co INVESTMENT ADVISERS, INC. 0.73% 159,003 $5.0M
16 AlphaCentric Advisors LLC 0.63% 23,622 $742K
17 Polar Asset Management Partners Inc. 0.60% 1,150,300 $36.2M
18 Kennedy Capital Management LLC 0.48% 856,609 $26.9M
19 Linden Thomas Advisory Services, LLC 0.45% 176,004 $5.5M
20 Systematic Financial Management LP 0.42% 667,883 $21.0M
21 Abc Arbitrage SA 0.40% 117,681 $3.7M
22 Credit Industriel Et Commercial 0.39% 193,503 $6.1M
23 Wakefield Asset Management LLLP 0.38% 53,081 $1.7M
24 AQR Arbitrage LLC 0.30% 674,223 $21.2M
25 WINTON GROUP Ltd 0.29% 287,736 $9.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Catalyst Pharmaceuticals Inc (CPRX)

What does the Smart Money Trend signal show for CPRX?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CPRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CPRX?

Slight buying edge — 51% buying: Last quarter: 216 funds bought or added vs 208 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CPRX holders?

Elite ownership — 62% AUM from top-100 funds: 54 of 387 holders are among the 100 largest funds by AUM, controlling 62% of total institutional value in CPRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CPRX?

47% of holders stayed for 2+ years: 184 out of 388 hedge funds have held CPRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →